Iterum Therapeutics plc (NASDAQ: ITRM)

Iterum Therapeutics plc, known by its ticker symbol ITRM, is a company that operates in the competitive and regulated pharmaceutical industry. The organization is focused on developing and commercializing sulopenem, a potent antibiotic that has the potential to address the growing concerns related to antibacterial resistance.

Iterum's main business activities are centered around the development and commercialization of sulopenem, a potent antibiotic that has the potential to address the growing concerns related to antibacterial resistance. This antibiotic is delivered intravenously and is active against bacteria that belong to the group of organisms known as gram-negatives, which are responsible for causing urinary tract and intra-abdominal infections. Iterum has also successfully developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is referred to as oral sulopenem.

The sulopenem program is a key segment of Iterum's business and includes the development of sulopenem delivered intravenously and sulopenem etzadroxil-probenecid, an oral tablet formulation. This program has the potential to address the unmet medical needs for patients suffering from uncomplicated and complicated infections in both the community and hospital settings.

Within the sulopenem program, there are two critical segments: the UTIs segment and the IAs segment. The UTIs segment focuses on the development and commercialization of sulopenem for the treatment of UTIs, which are a significant public health concern with approximately 15 million emergency room and office visits for symptoms of UTIs annually in the United States. The IAs segment focuses on the development and commercialization of sulopenem for the treatment of IAs, which are also a significant public health concern with approximately 3.6 million patients with cUTI and approximately 350,000 patients with cIAI that require antibiotic therapy every year in the United States.

Iterum's sulopenem program has several competitive advantages, including its potency against resistant pathogens, its spectrum of antibacterial activity, and its ability to be administered orally. These advantages make sulopenem a unique treatment option for patients suffering from UTIs and IAs. Additionally, Iterum's sulopenem program has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA, which provides certain incentives for the development of new antibiotics.

Iterum's customers are primarily healthcare providers, including physicians, hospitals, and clinics. The company's sulopenem program is designed to provide a treatment option for patients suffering from UTIs and IAs, and its customers are primarily those who treat these conditions.

Iterum's primary products are sulopenem and oral sulopenem. Sulopenem is a potent, thiopenem antibiotic delivered intravenously that is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. Oral sulopenem, also known as sulopenem etzadroxil-probenecid, is an oral tablet formulation of sulopenem.